Mapping PedsQL™ scores to CHU9D utility weights for children with chronic conditions in a multi-ethnic and deprived metropolitan population.


Journal

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
ISSN: 1573-2649
Titre abrégé: Qual Life Res
Pays: Netherlands
ID NLM: 9210257

Informations de publication

Date de publication:
Jul 2023
Historique:
accepted: 30 01 2023
medline: 7 6 2023
pubmed: 23 2 2023
entrez: 22 2 2023
Statut: ppublish

Résumé

The Child Health Utility-9 Dimensions (CHU9D) is a patient-reported outcome measure to generate Quality-Adjusted Life Years (QALYs), recommended for economic evaluations of interventions to inform funding decisions. When the CHU9D is not available, mapping algorithms offer an opportunity to convert other paediatric instruments, such as the Paediatric Quality of Life Inventory™ (PedsQL), onto the CHU9D scores. This study aims to validate current PedsQL to CHU9D mappings in a sample of children and young people of a wide age range (0 to 16 years of age) and with chronic conditions. New algorithms with improved predictive accuracy are also developed. Data from the Children and Young People's Health Partnership (CYPHP) were used (N = 1735). Four regression models were estimated: ordinal least squared, generalized linear model, beta-binomial and censored least absolute deviations. Standard goodness of fit measures were used for validation and to assess new algorithms. While previous algorithms perform well, performance can be enhanced. OLS was the best estimation method for the final equations at the total, dimension and item PedsQL scores levels. The CYPHP mapping algorithms include age as an important predictor and more non-linear terms compared with previous work. The new CYPHP mappings are particularly relevant for samples with children and young people with chronic conditions living in deprived and urban settings. Further validation in an external sample is required. Trial registration number NCT03461848; pre-results.

Identifiants

pubmed: 36814010
doi: 10.1007/s11136-023-03359-4
pii: 10.1007/s11136-023-03359-4
pmc: PMC10241699
doi:

Banques de données

ClinicalTrials.gov
['NCT03461848']

Types de publication

Clinical Trial Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1909-1923

Informations de copyright

© 2023. The Author(s).

Références

Appl Health Econ Health Policy. 2011 May 1;9(3):157-69
pubmed: 21506622
Value Health. 2012 Dec;15(8):1092-9
pubmed: 23244812
Qual Life Res. 2009 Oct;18(8):1105-13
pubmed: 19693703
Int J Cancer Suppl. 1999;12:87-90
pubmed: 10679877
J Clin Epidemiol. 2004 Nov;57(11):1138-46
pubmed: 15567629
Med Care. 1999 Feb;37(2):126-39
pubmed: 10024117
Pharmacoeconomics. 2019 Sep;37(9):1139-1153
pubmed: 31161585
Qual Life Res. 2022 Jul;31(7):2167-2173
pubmed: 35247152
Ther Innov Regul Sci. 2021 Sep;55(5):1082-1095
pubmed: 34142363
Value Health. 2004 Jan-Feb;7(1):79-92
pubmed: 14720133
Value Health. 2017 Jan;20(1):18-27
pubmed: 28212961
Value Health. 2021 Mar;24(3):443-460
pubmed: 33641779
BMJ Open. 2019 Sep 3;9(8):e027301
pubmed: 31481366
Pharmacoeconomics. 2018 Apr;36(4):451-465
pubmed: 29264866
Med Care. 2001 Aug;39(8):800-12
pubmed: 11468499
Appl Health Econ Health Policy. 2019 Jun;17(3):295-313
pubmed: 30945127
Pharmacoeconomics. 2017 Apr;35(4):453-467
pubmed: 27928758
Qual Life Res. 2020 Mar;29(3):639-652
pubmed: 31745690
NPJ Prim Care Respir Med. 2017 Sep 11;27(1):53
pubmed: 28894094
Health Qual Life Outcomes. 2015 Feb 18;13:22
pubmed: 25890377
Pharmacoeconomics. 2006;24(12):1199-220
pubmed: 17129075
Value Health. 2013 Jan-Feb;16(1):202-10
pubmed: 23337232
Fam Med Community Health. 2020 Feb 16;8(1):e000262
pubmed: 32148735
Pharmacoeconomics. 2012 Aug 1;30(8):729-47
pubmed: 22788262
Health Qual Life Outcomes. 2009 Apr 17;7:33
pubmed: 19371444
BMC Pediatr. 2015 Dec 16;15:211
pubmed: 26671226
Pharmacoeconomics. 2012 Aug 1;30(8):713-27
pubmed: 22788261
Qual Life Res. 2018 Jul;27(7):1769-1780
pubmed: 29564713
Patient Educ Couns. 2000 May;40(2):151-62
pubmed: 10771369

Auteurs

Clare B Kelly (CB)

Institute for Women and Children's Health, King's Health Partners, London, UK.
Department of Women's and Children's Health, School of Life Course and Population Sciences, King's College London, London, UK.

Marina Soley-Bori (M)

Institute for Women and Children's Health, King's Health Partners, London, UK. Marina.soley_bori@kcl.ac.uk.
Department of Population Health, School of Life Course and Population Sciences, King's College London, London, UK. Marina.soley_bori@kcl.ac.uk.
Faculty of Life Sciences and Medicine, School of Life Course & Population Sciences, King's College London, Guy's Campus, Great Maze Pond, London, SE1 1UL, UK. Marina.soley_bori@kcl.ac.uk.

Raghu Lingam (R)

School of Women's and Children's Health, University of New South Wales, Sydney, Australia.

Julia Forman (J)

Institute for Women and Children's Health, King's Health Partners, London, UK.
Department of Women's and Children's Health, School of Life Course and Population Sciences, King's College London, London, UK.

Lizzie Cecil (L)

Institute for Women and Children's Health, King's Health Partners, London, UK.
Department of Women's and Children's Health, School of Life Course and Population Sciences, King's College London, London, UK.

James Newham (J)

Faculty of Health and Life Sciences, Northumbria University, Newcastle upon Tyne, UK.

Ingrid Wolfe (I)

Institute for Women and Children's Health, King's Health Partners, London, UK.
Department of Women's and Children's Health, School of Life Course and Population Sciences, King's College London, London, UK.

Julia Fox-Rushby (J)

Department of Population Health, School of Life Course and Population Sciences, King's College London, London, UK.
NIHR Biomedical Research Centre, Guy's and St Thomas' NHS Foundation Trust and King's College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH